Overview
4cell Therapies is a company that develops CAR-T therapies for treating solid tumors, including challenging cases like pancreatic cancer, and hematological cancers such as leukemia and lymphoma. The company conducts research and development in Poland, utilizing advanced genetic engineering to create antigen receptors that target and destroy cancer cells. They also optimize production processes to meet GMP standards, ensuring scalability for future commercialization.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Industry
Bank accounts
Registered as a VAT taxpayer on 2013-02-07. Active
02 1750 1211 0000 0000 3066 1052- 50 1750 1211 0000 0000 3346 3197
- 55 1750 1211 0000 0000 3066 1068
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
No public aid cases recorded in the last 10 years.
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-03-01 | Rozwój nowej, skutecznej i wysoce specyficznej terapii nowotworów piersi o potencjalnie niskiej toksyczności, w oparciu o opatentowaną platformę technologiczną DOS47, modyfikującej mikrośrodowisko guza i odpowiedź immunologiczną poprzez zmianę pH. | $3.2M$3,171,859 | Program Operacyjny Inteligentny Rozwój |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
1. The submission of declarations on behalf of the company requires the joint action of two members of the management board, or of one member of the management board jointly with a commercial proxy. 2. If the management board is a one-person management board, one member of the management board is authorized to submit declarations on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights | |
|---|---|---|
Mary May Rodriguez (34)  | Beneficjent rzeczywisty osoby prawnej - spółki capeman investments limited posiadającej ok. 28,01% udziału w kapitale zakładowym 4cell therapies s.a. | |
Tadeusz Wesołowski (72)  | Shareholder of a joint-stock company, 40.95% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Zawamedsp. z o.o. | $43,909.06 | zawamed.pl | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| InventroS.A. | $12,176.61 | inventro.co | ||
| AI4Isp. z o.o. | $8,770.79 | ai4i.pl | ||
| Oncotherics PolandS.A. | $7,565.33 | oncotherics.com | ||
| Jotachemsp. z o.o. | $6,512.58 | jotachem.pl | ||
| Fusiomicasp. z o.o. | $5,263.98 | fusiomica.com | ||
| 4ATsp. z o.o. | $4,252.39 | 4at.pl | ||
| Poltisssp. z o.o. | $3,843.72 | poltiss.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-10 | Share capital change (2,520,815.60 PLN → 3,172,432.10 PLN) | |
| 2026-05-15 | Share capital change (2,065,653.70 PLN → 2,520,815.60 PLN) | |
| 2023-12-27 | Share capital change (1,880,468.50 PLN → 2,065,653.70 PLN) | |
| 2021-06-07 | Name change (Helix Immuno-Oncology → 4cell Therapies) | |
| 2020-10-27 | Share capital change (1,321,950.00 PLN → 1,880,468.50 PLN) |
FAQ
Last updated: 2026-09-10